EA201790653A1 - Способ лечения болезни альцгеймера и других расстройств - Google Patents

Способ лечения болезни альцгеймера и других расстройств

Info

Publication number
EA201790653A1
EA201790653A1 EA201790653A EA201790653A EA201790653A1 EA 201790653 A1 EA201790653 A1 EA 201790653A1 EA 201790653 A EA201790653 A EA 201790653A EA 201790653 A EA201790653 A EA 201790653A EA 201790653 A1 EA201790653 A1 EA 201790653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
alzheimer
disorders
treatment
glyx
Prior art date
Application number
EA201790653A
Other languages
English (en)
Inventor
Джозеф Москал
Original Assignee
Нортвестерн Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нортвестерн Юниверсити filed Critical Нортвестерн Юниверсити
Publication of EA201790653A1 publication Critical patent/EA201790653A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способам лечения болезни Альцгеймера или потери памяти, которая сопровождает раннюю стадию болезни Альцгеймера, у нуждающегося в этом пациента путем введения эффективного количества частичного агониста глицинового сайта NMDA-рецептора, такого как GLYX-13или его фармацевтически приемлемой соли.
EA201790653A 2011-04-27 2012-04-27 Способ лечения болезни альцгеймера и других расстройств EA201790653A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US201161527744P 2011-08-26 2011-08-26

Publications (1)

Publication Number Publication Date
EA201790653A1 true EA201790653A1 (ru) 2017-07-31

Family

ID=47073094

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201391581A EA029999B1 (ru) 2011-04-27 2012-04-27 Способы лечения аутизма
EA201790653A EA201790653A1 (ru) 2011-04-27 2012-04-27 Способ лечения болезни альцгеймера и других расстройств

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201391581A EA029999B1 (ru) 2011-04-27 2012-04-27 Способы лечения аутизма

Country Status (13)

Country Link
US (4) US20140107037A1 (ru)
EP (2) EP2701721A4 (ru)
JP (1) JP6035326B2 (ru)
KR (5) KR20190037359A (ru)
CN (2) CN103974712A (ru)
AU (1) AU2012249397B2 (ru)
BR (1) BR112013027554A2 (ru)
CA (1) CA2834286A1 (ru)
EA (2) EA029999B1 (ru)
HK (1) HK1258231A1 (ru)
MX (1) MX357761B (ru)
SG (2) SG194230A1 (ru)
WO (1) WO2012149389A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
JP2016506958A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
BR112015018094A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
KR20160077153A (ko) 2013-10-28 2016-07-01 노렉스, 인크. Nmda 수용체 조절인자 및 이들의 전구약물, 염, 그리고 용도
CA2933372A1 (en) * 2013-12-13 2015-06-18 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
RU2721401C2 (ru) * 2014-06-23 2020-05-19 Нортвестерн Юниверсити Способы лечения или облегчения мигрени
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
EA201990428A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
JP2019527233A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
KR20200115611A (ko) 2018-01-31 2020-10-07 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
ES2428313T3 (es) * 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente
US9783851B2 (en) * 2008-02-20 2017-10-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
PT2485751E (pt) * 2009-10-05 2014-09-01 Univ Northwestern Glyx-13 para uso num método para tratar depressão refratária

Also Published As

Publication number Publication date
SG194230A1 (en) 2013-12-30
US20210169964A1 (en) 2021-06-10
AU2012249397A1 (en) 2013-11-07
WO2012149389A2 (en) 2012-11-01
MX357761B (es) 2018-07-23
CN103974712A (zh) 2014-08-06
EP3679931A3 (en) 2020-10-14
EA201391581A1 (ru) 2014-05-30
US20140107037A1 (en) 2014-04-17
KR20190037359A (ko) 2019-04-05
JP6035326B2 (ja) 2016-11-30
EA029999B1 (ru) 2018-06-29
US20170049845A1 (en) 2017-02-23
EP2701721A2 (en) 2014-03-05
WO2012149389A3 (en) 2014-05-08
KR20180095096A (ko) 2018-08-24
KR20140043078A (ko) 2014-04-08
HK1258231A1 (zh) 2019-11-08
BR112013027554A2 (pt) 2016-09-06
AU2012249397B2 (en) 2017-03-30
KR20210046843A (ko) 2021-04-28
CN108283712A (zh) 2018-07-17
CA2834286A1 (en) 2012-11-01
KR20200043534A (ko) 2020-04-27
EP2701721A4 (en) 2015-12-16
SG10202010665YA (en) 2020-11-27
MX2013012526A (es) 2014-04-16
EP3679931A2 (en) 2020-07-15
JP2014520072A (ja) 2014-08-21
US20190209642A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201892339A2 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201101507A1 (ru) Способы лечения солидных опухолей
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201290603A1 (ru) Способ лечения
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии